Approximately 5,000-8,000 distinct rare diseases affect 6-8% of the EU population i.e. between 27 and 36 million people. Any disease affecting fewer than 5 people in 10,000 in the EU is considered rare. Although this might appear small, it translates into approximately 246,000 people. Nowadays around the 50% of the medicines addressed to children and young patients have not been tested specifically for them.
The main topics that will be discussed during the 1st International Conference on Rare Diseases and Paediatric Research that will take place virtually on the 18th and 19th of November 2021 are:
-the future of the Regulatory framework.
-supporting tools and funding opportunities in RD and Paediatric Research.
-regulatory tools to speed up orphan and paediatric medicines development.
-clinical Trials and non-clinical research: the role of Networks and Infrastructures.
-RD and Paediatric Research during the COVID-19 pandemic.
The Conference is supported by Athena RIC (Research and Innovation Center in Information, Communication and Knowledge Technologies), TEDDY (European Network of Excellence for Paediatric Research), EPF (European Patients Forum), EUPATI Greece (European Patients’ Academy on Therapeutic Innovation) and organised by CVBF (Consorzio per Valutazioni Biologiche e Farmacologiche) and 95, Rare Alliance Greece, member of EURORDIS.
The preliminary programme is available here!
To register click here!